

## RELEVANT EVENT

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. (the "**Company**") hereby informs that:

Grifols has entered into an Agreement to exclusively manufacture and supply plasma derived products for the biosurgery field to Ethicon Inc. The Agreement to supply is dependent upon approval of the products by the relevant regulatory authorities. The Agreement is for an initial term of 10 years with subsequent 5-year renewal periods. The Agreement calls for the payment of certain milestones upon regulatory approval and annual sales based upon forecasts.

In Barcelona, on 7 June 2017

---

Núria Martín Barnés  
Secretary to the Board of Directors